IPCA Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ipca Laboratories has submitted copies of its unaudited financial results for Q1 FY26 (quarter ended 30 June 2025) as published in Business Standard and Nav Shakti newspapers on 12 August 2025, in compliance with SEBI Listing Regulations. On a consolidated basis, total income from operations rose to ₹2,308.85 crore from ₹2,092.63 crore in Q1 FY25, a growth of about 10%. Net profit after tax (after exceptional items) stood at ₹233.21 crore versus ₹192.24 crore a year ago, up roughly 21%. Basic and diluted EPS (before exceptional items) came in at ₹9.19 compared to ₹7.58 in the year-ago quarter. On a standalone basis, profit after tax was ₹262.04 crore versus ₹204.13 crore, growth of nearly 28%.
This is a routine compliance filing that simply republishes already-disclosed quarterly numbers in newspapers, so it is unlikely to move the stock on its own. However, the underlying Q1 numbers show healthy double-digit growth in both revenue and profit, which is mildly positive for shareholders and reinforces the company's earnings momentum.